[{"id":"a24dd70d-457e-4bf3-b1b4-2106aa67a692","acronym":"","url":"https://clinicaltrials.gov/study/NCT07064018","created_at":"2025-07-19T14:18:32.626Z","updated_at":"2025-07-19T14:18:32.626Z","phase":"Phase 1/2","brief_title":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","source_id_and_acronym":"NCT07064018","lead_sponsor":"University of California, Irvine","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2031","study_completion_date":" 12/31/2031","last_update_posted":"2025-07-14"},{"id":"99c4032a-3714-4351-a6af-2208fcba233e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684368","created_at":"2021-01-19T20:47:18.675Z","updated_at":"2025-02-25T15:11:50.245Z","phase":"Phase 2","brief_title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","source_id_and_acronym":"NCT04684368","lead_sponsor":"Children's Oncology Group","biomarkers":" NF1","pipe":" | ","alterations":" AFP elevation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cyclophosphamide • ifosfamide • etoposide IV • mesna • thiotepa • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 07/13/2021","start_date":" 07/13/2021","primary_txt":" Primary completion: 12/21/2029","primary_completion_date":" 12/21/2029","study_txt":" Completion: 12/21/2029","study_completion_date":" 12/21/2029","last_update_posted":"2025-02-13"},{"id":"5351b2fd-adc5-41e4-92bd-076122f48c07","acronym":"BRI-ROL-001","url":"https://clinicaltrials.gov/study/NCT03328026","created_at":"2021-01-18T16:26:04.427Z","updated_at":"2025-02-25T16:52:02.280Z","phase":"Phase 1/2","brief_title":"Combination Study of SV-BR-1-GM With Retifanlimab","source_id_and_acronym":"NCT03328026 - BRI-ROL-001","lead_sponsor":"BriaCell Therapeutics Corporation","biomarkers":" ER • PIK3CA • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • Bria-IMT (SV-BR-1-GM) • Intron A (interferon α-2b) • cyclophosphamide intravenous"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 36","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 11/03/2025","primary_completion_date":" 11/03/2025","study_txt":" Completion: 11/30/2028","study_completion_date":" 11/30/2028","last_update_posted":"2025-02-04"},{"id":"aad15df4-1ae3-483a-b0fd-2eaad8e9fe6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06520176","created_at":"2025-02-27T07:53:36.469Z","updated_at":"2025-02-27T07:53:36.469Z","phase":"Phase 3","brief_title":"Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients","source_id_and_acronym":"NCT06520176","lead_sponsor":"The Affiliated People's Hospital of Ningbo University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • etoposide IV • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-07-25"},{"id":"bd75f6cb-9c61-46b7-9c32-2458d8550dad","acronym":"BRIA-ABC","url":"https://clinicaltrials.gov/study/NCT06072612","created_at":"2023-10-10T15:12:12.246Z","updated_at":"2024-07-02T16:34:26.318Z","phase":"Phase 3","brief_title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","source_id_and_acronym":"NCT06072612 - BRIA-ABC","lead_sponsor":"BriaCell Therapeutics Corporation","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • capecitabine • cyclophosphamide • Halaven (eribulin mesylate) • Zynyz (retifanlimab-dlwr) • Bria-IMT (SV-BR-1-GM)"],"overall_status":"Recruiting","enrollment":" Enrollment 404","initiation":"Initiation: 12/05/2023","start_date":" 12/05/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-13"},{"id":"42b6baf8-4551-4b46-9aa7-65602da4a620","acronym":"","url":"https://clinicaltrials.gov/study/NCT05733611","created_at":"2023-02-17T15:01:01.140Z","updated_at":"2024-07-02T16:35:11.814Z","phase":"Phase 2","brief_title":"RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC","source_id_and_acronym":"NCT05733611","lead_sponsor":"Replimune Inc.","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • RP3 • sturlimogene erparepvec (RP2)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4","initiation":"Initiation: 06/29/2023","start_date":" 06/29/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-04-02"},{"id":"87bcd5d7-65b9-43a1-8517-f0ede1fe83cf","acronym":"NEUTHREE","url":"https://clinicaltrials.gov/study/NCT05949333","created_at":"2023-07-20T15:09:13.325Z","updated_at":"2024-07-02T16:35:17.796Z","phase":"Phase 4","brief_title":"Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy","source_id_and_acronym":"NCT05949333 - NEUTHREE","lead_sponsor":"Eunseong Medical Foundation Good GANG-AN HOSPITAL","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Rolvedon (eflapegrastim-xnst)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/07/2023","start_date":" 11/07/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-02-23"},{"id":"9fe13a84-7b08-4b51-b44b-278edc65a6ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT06116734","created_at":"2023-11-03T20:12:33.405Z","updated_at":"2024-07-02T16:35:30.385Z","phase":"Phase 3","brief_title":"Lapelga vs Gastrofil","source_id_and_acronym":"NCT06116734","lead_sponsor":"Lawson Health Research Institute","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-11-03"},{"id":"82c12a95-3544-4b96-aa4a-050f89916311","acronym":"","url":"https://clinicaltrials.gov/study/NCT05130827","created_at":"2021-11-23T13:53:28.519Z","updated_at":"2024-07-02T16:35:41.054Z","phase":"Phase 2","brief_title":"Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)","source_id_and_acronym":"NCT05130827","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plinabulin (BPI 2358) • Neulasta (pegfilgrastim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 12/21/2021","start_date":" 12/21/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-08-03"},{"id":"39becca5-f213-4136-89a7-2909836a7485","acronym":"","url":"https://clinicaltrials.gov/study/NCT05834751","created_at":"2023-04-28T15:04:43.092Z","updated_at":"2024-07-02T16:35:49.379Z","phase":"","brief_title":"the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma","source_id_and_acronym":"NCT05834751","lead_sponsor":"Ou Bai, MD/PHD","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Neupogen (filgrastim)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-04-28"},{"id":"7e4f81a6-72f5-4f86-a545-a5378d007797","acronym":"","url":"https://clinicaltrials.gov/study/NCT05463601","created_at":"2022-07-19T15:55:10.839Z","updated_at":"2024-07-02T16:35:50.729Z","phase":"Phase 2","brief_title":"Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer","source_id_and_acronym":"NCT05463601","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • letrozole • exemestane • AiRuiKang (dalpiciclib) • HHPG-19K (mecapegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-04-12"},{"id":"6db5c3f8-e3ab-4a02-ac01-26e44b4d72e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05007652","created_at":"2021-08-16T16:54:47.451Z","updated_at":"2024-07-02T16:35:55.110Z","phase":"Phase 2","brief_title":"A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma","source_id_and_acronym":"NCT05007652","lead_sponsor":"Kyowa Kirin Co., Ltd.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Neupogen (filgrastim) • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 10/25/2022","primary_completion_date":" 10/25/2022","study_txt":" Completion: 10/25/2022","study_completion_date":" 10/25/2022","last_update_posted":"2023-02-21"},{"id":"34b87302-7697-4b60-8b03-5b5bf404028e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03889275","created_at":"2021-01-18T19:09:59.243Z","updated_at":"2024-07-02T16:35:55.143Z","phase":"Phase 1","brief_title":"A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors","source_id_and_acronym":"NCT03889275","lead_sponsor":"MedImmune LLC","biomarkers":" PD-L1 • CD8","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • MEDI5395"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 10/24/2019","start_date":" 10/24/2019","primary_txt":" Primary completion: 11/19/2021","primary_completion_date":" 11/19/2021","study_txt":" Completion: 12/12/2022","study_completion_date":" 12/12/2022","last_update_posted":"2023-02-20"},{"id":"dd0ebb9d-78f3-4a27-a09b-20c1b897898e","acronym":"BREASTIMMU02","url":"https://clinicaltrials.gov/study/NCT03571633","created_at":"2021-01-18T17:34:31.757Z","updated_at":"2024-07-02T16:35:57.881Z","phase":"Phase 2","brief_title":"Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer","source_id_and_acronym":"NCT03571633 - BREASTIMMU02","lead_sponsor":"Centre Leon Berard","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/06/2018","start_date":" 08/06/2018","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2023-01-10"},{"id":"4d4aa8d5-9575-498a-a4a0-d10dc78114a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05294055","created_at":"2022-03-24T13:52:36.811Z","updated_at":"2024-07-02T16:35:59.720Z","phase":"Phase 2","brief_title":"Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma","source_id_and_acronym":"NCT05294055","lead_sponsor":"Qiu Lugui","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • HHPG-19K (mecapegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/26/2022","start_date":" 04/26/2022","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2022-12-02"},{"id":"100d53c1-a871-4c02-b038-7972188d3735","acronym":"","url":"https://clinicaltrials.gov/study/NCT03317899","created_at":"2021-01-18T16:23:07.420Z","updated_at":"2024-07-02T16:36:00.230Z","phase":"Phase 2","brief_title":"Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03317899","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neupogen (filgrastim) • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 10/12/2017","start_date":" 10/12/2017","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 11/16/2022","study_completion_date":" 11/16/2022","last_update_posted":"2022-11-17"},{"id":"a0241a75-1e8f-40d4-9fa9-1f6411819b0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00911183","created_at":"2021-01-18T03:31:16.959Z","updated_at":"2024-07-02T16:36:08.954Z","phase":"Phase 2","brief_title":"Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial","source_id_and_acronym":"NCT00911183","lead_sponsor":"Institut Bergonié","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • vincristine • prednisone • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 12/02/2008","start_date":" 12/02/2008","primary_txt":" Primary completion: 12/31/2012","primary_completion_date":" 12/31/2012","study_txt":" Completion: 01/01/2015","study_completion_date":" 01/01/2015","last_update_posted":"2022-06-14"},{"id":"03612bf2-20b6-49e7-818d-3e1901de8a18","acronym":"","url":"https://clinicaltrials.gov/study/NCT00193479","created_at":"2021-01-18T00:39:26.867Z","updated_at":"2024-07-02T16:36:16.128Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00193479","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • vincristine • prednisone • mitoxantrone • Neulasta (pegfilgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 04/01/2003","start_date":" 04/01/2003","primary_txt":" Primary completion: 07/01/2008","primary_completion_date":" 07/01/2008","study_txt":" Completion: 02/01/2010","study_completion_date":" 02/01/2010","last_update_posted":"2022-03-03"},{"id":"5654fbf7-fb7d-419d-acfc-f2531c39d7ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT00726700","created_at":"2021-01-18T02:44:08.050Z","updated_at":"2024-07-02T16:36:28.234Z","phase":"Phase 2","brief_title":"Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT00726700","lead_sponsor":"Universität des Saarlandes","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Neulasta (pegfilgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 109","initiation":"Initiation: 05/01/2004","start_date":" 05/01/2004","primary_txt":" Primary completion: 02/01/2012","primary_completion_date":" 02/01/2012","study_txt":" Completion: 02/01/2012","study_completion_date":" 02/01/2012","last_update_posted":"2021-07-07"},{"id":"7f86cc3f-f36b-43ca-a75f-ceecaeea4f8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01787474","created_at":"2022-07-13T07:55:08.172Z","updated_at":"2024-07-02T16:36:28.828Z","phase":"Phase 1/2","brief_title":"Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT01787474","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KIR2DS2","pipe":"","alterations":" ","tags":["KIR2DS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 05/19/2014","start_date":" 05/19/2014","primary_txt":" Primary completion: 06/17/2021","primary_completion_date":" 06/17/2021","study_txt":" Completion: 06/17/2021","study_completion_date":" 06/17/2021","last_update_posted":"2021-06-21"},{"id":"56840cd1-de4a-4f57-9498-f5727132e914","acronym":"","url":"https://clinicaltrials.gov/study/NCT04418219","created_at":"2021-01-18T21:17:41.922Z","updated_at":"2024-07-02T16:36:29.480Z","phase":"Phase 1/2","brief_title":"Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer","source_id_and_acronym":"NCT04418219","lead_sponsor":"Thomas Jefferson University","biomarkers":" HER-2 • PD-L1 • ER • PGR • PD-L2 • HLA-B • PRAME • HLA-C","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • ER positive + PGR positive • PGR positive • PGR negative • HLA-A*24","tags":["HER-2 • PD-L1 • ER • PGR • PD-L2 • HLA-B • PRAME • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • ER positive + PGR positive • PGR positive • PGR negative • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • Bria-IMT (SV-BR-1-GM) • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/21/2020","start_date":" 12/21/2020","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2021-06-07"},{"id":"9805fea0-f815-4c7a-a68c-d5dbb3e1606c","acronym":"Def_Special","url":"https://clinicaltrials.gov/study/NCT04905329","created_at":"2021-05-27T12:53:12.462Z","updated_at":"2024-07-02T16:36:29.623Z","phase":"","brief_title":"A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations","source_id_and_acronym":"NCT04905329 - Def_Special","lead_sponsor":"Moscow Clinical Scientific Center","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"],"overall_status":"Recruiting","enrollment":" Enrollment 285","initiation":"Initiation: 04/28/2020","start_date":" 04/28/2020","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2021-06-02"},{"id":"834d33c7-17a0-4ad7-9656-e5d2614ebdcb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01671319","created_at":"2021-01-18T07:13:51.786Z","updated_at":"2024-07-02T16:36:53.160Z","phase":"Phase 2","brief_title":"Dose Dense TC + Pegfilgrastim Support for Breast Cancer","source_id_and_acronym":"NCT01671319","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" HER-2 • ER • ALK • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cyclophosphamide • Neulasta (pegfilgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 04/01/2013","study_completion_date":" 04/01/2013","last_update_posted":"2019-11-27"},{"id":"abad0806-f54e-4f8b-88af-6374bf415a5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02650193","created_at":"2021-01-18T12:54:01.849Z","updated_at":"2024-07-02T16:37:05.837Z","phase":"Phase 2","brief_title":"A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.","source_id_and_acronym":"NCT02650193","lead_sponsor":"Pfizer","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neupogen (filgrastim) • Nyvepria (pegfilgrastim-apgf)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 10/01/2017","study_completion_date":" 10/01/2017","last_update_posted":"2018-10-23"}]